Literature DB >> 19453285

Post-traumatic stress disorder: emerging concepts of pharmacotherapy.

Dewleen G Baker1, Caroline M Nievergelt, Victoria B Risbrough.   

Abstract

Post-traumatic stress disorder (PTSD) can result from a traumatic experience that elicits emotions of fear, helpless or horror. Most individuals remain asymptomatic or symptoms quickly resolve, but in a minority intrusive imagery and nightmares, emotional numbing and avoidance, and hyperarousal persist for decades. PTSD is associated with psychiatric and medical co-morbidities, increased risk for suicide, and with poor social and occupational functioning. Psychotherapy and pharmacotherapy are common treatments. Whereas, research supports the efficacy of the cognitive behavioral psychotherapies, there is insufficient evidence to unequivocally support the efficacy of any specific pharmacotherapy. Proven effective pharmacologic agents are sorely needed to treat core and targeted PTSD symptoms, and for prevention. This review describes current and emerging pharmacotherapies that advance these goals.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19453285      PMCID: PMC2791537          DOI: 10.1517/14728210902972494

Source DB:  PubMed          Journal:  Expert Opin Emerg Drugs        ISSN: 1472-8214            Impact factor:   4.191


  196 in total

1.  Prewar factors in combat-related posttraumatic stress disorder: structural equation modeling with a national sample of female and male Vietnam veterans.

Authors:  D W King; L A King; D W Foy; D M Gudanowski
Journal:  J Consult Clin Psychol       Date:  1996-06

2.  Post-traumatic stress disorder in Canada.

Authors:  Michael Van Ameringen; Catherine Mancini; Beth Patterson; Michael H Boyle
Journal:  CNS Neurosci Ther       Date:  2008       Impact factor: 5.243

3.  Treatment of anxiety using fenobam (a nonbenzodiazepine) in a double-blind standard (diazepam) placebo-controlled study.

Authors:  J C Pecknold; D J McClure; L Appeltauer; L Wrzesinski; T Allan
Journal:  J Clin Psychopharmacol       Date:  1982-04       Impact factor: 3.153

4.  Comorbidity, impairment, and suicidality in subthreshold PTSD.

Authors:  R D Marshall; M Olfson; F Hellman; C Blanco; M Guardino; E L Struening
Journal:  Am J Psychiatry       Date:  2001-09       Impact factor: 18.112

5.  Anxiety disorders associated with suicidal ideation and suicide attempts in the National Comorbidity Survey.

Authors:  Jitender Sareen; Tanya Houlahan; Brian J Cox; Gordon J G Asmundson
Journal:  J Nerv Ment Dis       Date:  2005-07       Impact factor: 2.254

6.  Gene-environment interaction analysis of serotonin system markers with adolescent depression.

Authors:  T C Eley; K Sugden; A Corsico; A M Gregory; P Sham; P McGuffin; R Plomin; I W Craig
Journal:  Mol Psychiatry       Date:  2004-10       Impact factor: 15.992

7.  Corticotropin-releasing factor in posttraumatic stress disorder (PTSD) with secondary psychotic symptoms, nonpsychotic PTSD, and healthy control subjects.

Authors:  Frederic J Sautter; Garth Bissette; Justin Wiley; Gina Manguno-Mire; Benjamin Schoenbachler; Leann Myers; Janet E Johnson; Arleen Cerbone; Dolores Malaspina
Journal:  Biol Psychiatry       Date:  2003-12-15       Impact factor: 13.382

8.  Diagnostic co-morbidity in 2300 psychiatric out-patients presenting for treatment evaluated with a semi-structured diagnostic interview.

Authors:  M Zimmerman; J B McGlinchey; I Chelminski; D Young
Journal:  Psychol Med       Date:  2007-10-22       Impact factor: 7.723

9.  The serotonin transporter genotype and social support and moderation of posttraumatic stress disorder and depression in hurricane-exposed adults.

Authors:  Dean G Kilpatrick; Karestan C Koenen; Kenneth J Ruggiero; Ron Acierno; Sandro Galea; Heidi S Resnick; John Roitzsch; John Boyle; Joel Gelernter
Journal:  Am J Psychiatry       Date:  2007-11       Impact factor: 18.112

Review 10.  Endocannabinoid system and synaptic plasticity: implications for emotional responses.

Authors:  María-Paz Viveros; Eva-María Marco; Ricardo Llorente; Meritxell López-Gallardo
Journal:  Neural Plast       Date:  2007       Impact factor: 3.599

View more
  9 in total

Review 1.  Pharmacological treatment of PTSD - established and new approaches.

Authors:  Thomas Steckler; Victoria Risbrough
Journal:  Neuropharmacology       Date:  2011-06-29       Impact factor: 5.250

2.  Consolidation of remote fear memories involves Corticotropin-Releasing Hormone (CRH) receptor type 1-mediated enhancement of AMPA receptor GluR1 signaling in the dentate gyrus.

Authors:  Christoph K Thoeringer; Kathrin Henes; Matthias Eder; Maik Dahlhoff; Wolfgang Wurst; Florian Holsboer; Jan M Deussing; Sven Moosmang; Carsten T Wotjak
Journal:  Neuropsychopharmacology       Date:  2011-10-26       Impact factor: 7.853

Review 3.  Hippocampal dysfunction effects on context memory: possible etiology for posttraumatic stress disorder.

Authors:  Dean T Acheson; Jodi E Gresack; Victoria B Risbrough
Journal:  Neuropharmacology       Date:  2011-05-11       Impact factor: 5.250

4.  Environmental enrichment induces behavioral recovery and enhanced hippocampal cell proliferation in an antidepressant-resistant animal model for PTSD.

Authors:  Hendrikus Hendriksen; Jolanda Prins; Berend Olivier; Ronald S Oosting
Journal:  PLoS One       Date:  2010-08-05       Impact factor: 3.240

Review 5.  Recent progress in understanding the pathophysiology of post-traumatic stress disorder: implications for targeted pharmacological treatment.

Authors:  Christopher R Bailey; Elisabeth Cordell; Sean M Sobin; Alexander Neumeister
Journal:  CNS Drugs       Date:  2013-03       Impact factor: 5.749

Review 6.  Patient-reported outcomes in post-traumatic stress disorder. Part II: focus on pharmacological treatment.

Authors:  Hans-Peter Kapfhammer
Journal:  Dialogues Clin Neurosci       Date:  2014-06       Impact factor: 5.986

7.  Methylphenidate and desipramine combined treatment improves PTSD symptomatology in a rat model.

Authors:  S Aga-Mizrachi; A Cymerblit-Sabba; O Gurman; A Balan; G Shwam; R Deshe; L Miller; N Gorodetsky; N Heinrich; O Tzezana; S Zubedat; D Grinstein; A Avital
Journal:  Transl Psychiatry       Date:  2014-09-23       Impact factor: 6.222

8.  Ameliorating Impact of Prophylactic Intranasal Oxytocin on Signs of Fear in a Rat Model of Traumatic Stress.

Authors:  Micah D Renicker; Nicholas Cysewski; Samuel Palmer; Dmytro Nakonechnyy; Andrew Keef; Morgan Thomas; Krisztian Magori; David P Daberkow
Journal:  Front Behav Neurosci       Date:  2018-05-28       Impact factor: 3.558

9.  Dynamic Patterns of Threat-Associated Gene Expression in the Amygdala and Blood.

Authors:  Adriana Lori; Stephanie A Maddox; Sumeet Sharma; Raül Andero; Kerry J Ressler; Alicia K Smith
Journal:  Front Psychiatry       Date:  2019-01-17       Impact factor: 4.157

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.